Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$26.61 -1.6%	$24.40	$20.92 ▼ $42.48	$50.78B	N/A	277,258 shs	121,705 shs
MKKGY Merck KGaA	$26.28 +0.1%	$26.83	$24.32 ▼ $39.17	$16.98B	0.96	131,869 shs	250,645 shs
REGN Regeneron Pharmaceuticals	$493.24 -18.5%	$584.25	$485.00 ▼ $1,211.20	$52.93B	0.43	829,463 shs	6.31 million shs
TAK Takeda Pharmaceutical	$15.01 +1.4%	$14.66	$12.58 ▼ $15.43	$47.76B	0.26	1.94 million shs	1.73 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	0.00%	+1.03%	+4.89%	+15.95%	-22.28%
MKKGY Merck KGaA	0.00%	+1.12%	-4.84%	-6.83%	-27.82%
REGN Regeneron Pharmaceuticals	0.00%	-16.16%	-16.40%	-29.41%	-48.97%
TAK Takeda Pharmaceutical	0.00%	+2.98%	-0.10%	+4.24%	+16.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MKKGY Merck KGaA	2.1949 of 5 stars	0.0	3.0	2.5	0.0	1.8	0.0	2.5
REGN Regeneron Pharmaceuticals	4.8522 of 5 stars	4.4	4.0	1.7	2.3	3.0	1.7	1.9
TAK Takeda Pharmaceutical	2.825 of 5 stars	0.0	3.0	2.5	0.0	3.4	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSNKY Daiichi Sankyo	0.00	N/A	N/A	N/A
MKKGY Merck KGaA	3.00	Buy	N/A	N/A
REGN Regeneron Pharmaceuticals	2.85	Moderate Buy	$874.56	77.31% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest MKKGY, REGN, DSNKY, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/30/2025	REGN Regeneron Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$662.00
5/30/2025	REGN Regeneron Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$700.00 ➝ $580.00
5/27/2025	REGN Regeneron Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Sector Perform	$943.00 ➝ $662.00
5/14/2025	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$600.00 ➝ $700.00
5/1/2025	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$940.00 ➝ $810.00
4/30/2025	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$975.00 ➝ $940.00
4/30/2025	REGN Regeneron Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$917.00 ➝ $804.00
4/30/2025	REGN Regeneron Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$750.00 ➝ $700.00
4/30/2025	REGN Regeneron Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$1,051.00 ➝ $943.00
4/2/2025	TAK Takeda Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight

(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSNKY Daiichi Sankyo	$11.09B	4.58	N/A	N/A	$5.62 per share	4.73
MKKGY Merck KGaA	$22.72B	0.75	$9.59 per share	2.74	N/A	∞
REGN Regeneron Pharmaceuticals	$14.09B	3.78	$32.39 per share	15.23	$268.50 per share	1.84
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.52 per share	4.27	$15.39 per share	0.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSNKY Daiichi Sankyo	$1.39B	$1.03	30.94	24.41	1.72	13.62%	14.53%	7.07%	7/29/2025 (Estimated)
MKKGY Merck KGaA	$3.06B	$2.11	16.22	12.82	2.05	12.89%	10.41%	5.88%	8/7/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	12.89	12.97	2.34	31.07%	16.32%	12.76%	8/7/2025 (Estimated)
TAK Takeda Pharmaceutical	$994.06M	$0.22	37.53	9.10	0.24	4.53%	9.39%	4.53%	7/30/2025 (Estimated)

Latest MKKGY, REGN, DSNKY, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	MKKGY Merck KGaA	$0.50	$0.59	+$0.09	$0.59	$5.32 billion	$5.89 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion
4/25/2025	Q4 2025	DSNKY Daiichi Sankyo	N/A	$0.30	N/A	$0.30	N/A	$3.40 billion
3/6/2025	Q4 2024	MKKGY Merck KGaA	$0.47	$0.54	+$0.07	$0.54	$5.40 billion	$5.78 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A
MKKGY Merck KGaA	$0.33	1.26%	N/A	15.64%	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.71%	N/A	8.96%	N/A
TAK Takeda Pharmaceutical	$0.53	3.53%	-8.36%	240.91%	N/A

Latest MKKGY, REGN, DSNKY, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025
4/23/2025	MKKGY Merck KGaA		$0.3382	1.25%	4/29/2025	4/30/2025	5/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSNKY Daiichi Sankyo	0.06	2.77	2.11
MKKGY Merck KGaA	0.28	1.33	0.91
REGN Regeneron Pharmaceuticals	0.09	4.73	3.95
TAK Takeda Pharmaceutical	0.63	1.31	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSNKY Daiichi Sankyo	N/A
MKKGY Merck KGaA	0.10%
REGN Regeneron Pharmaceuticals	83.31%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
DSNKY Daiichi Sankyo	N/A
MKKGY Merck KGaA	N/A
REGN Regeneron Pharmaceuticals	7.02%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSNKY Daiichi Sankyo	17,435	1.91 billion	N/A	Not Optionable
MKKGY Merck KGaA	62,908	646.21 million	N/A	Not Optionable
REGN Regeneron Pharmaceuticals	11,900	107.97 million	101.15 million	Optionable
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable

MKKGY, REGN, DSNKY, and TAK Headlines

Recent News About These Companies

At the WBUR Festival, exploring the good and bad scenarios for Massachusetts’ future

May 31 at 8:28 AM | msn.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Summit Global Investments

May 31 at 6:55 AM | marketbeat.com

Toronto Dominion Bank Takes $6.76 Million Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 31 at 4:27 AM | marketbeat.com

Two Sigma Advisers LP Increases Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 30 at 3:54 AM | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Bank of America Corp DE

May 30 at 3:16 AM | marketbeat.com

The Escalator: Acadia Pharmaceuticals, Indivior, Takeda and more

May 29 at 8:57 AM | mmm-online.com

Voloridge Investment Management LLC Raises Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 28, 2025 | marketbeat.com

Forum Financial Management LP Raises Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 27, 2025 | marketbeat.com

GTS Securities LLC Makes New Investment in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 27, 2025 | marketbeat.com

26,600 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by Point72 Asset Management L.P.

May 26, 2025 | marketbeat.com

510,600 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Acquired by Toronto Dominion Bank

May 24, 2025 | marketbeat.com

First AI-generated drugs may reach market by 2030: Insilico CEO

May 23, 2025 | moneyweb.co.za

First AI-generated drugs could go on sale by 2030

May 22, 2025 | techcentral.co.za

Millennium Management LLC Sells 1,655,703 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 22, 2025 | marketbeat.com

Janus Henderson Group PLC Has $3.10 Million Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 22, 2025 | marketbeat.com

Soleus Capital Management L.P. Purchases 680,000 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 21, 2025 | marketbeat.com

Focus Partners Wealth Raises Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 20, 2025 | marketbeat.com

Quantinno Capital Management LP Increases Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 19, 2025 | marketbeat.com

Dimensional Fund Advisors LP Increases Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 17, 2025 | marketbeat.com

230,000 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Purchased by LMR Partners LLP

May 15, 2025 | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Holdings Raised by Hudson Bay Capital Management LP

May 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Palantir Scores First $1 Billion Contract; Is It Priced In?
By Chris Markoch | May 27, 2025
View Palantir Scores First $1 Billion Contract; Is It Priced In?
Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
By Nathan Reiff | May 15, 2025
View Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025

MKKGY, REGN, DSNKY, and TAK Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

$26.61 -0.44 (-1.61%)

As of 05/30/2025 03:59 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Merck KGaA OTCMKTS:MKKGY

$26.28 +0.03 (+0.12%)

As of 05/30/2025 04:00 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Regeneron Pharmaceuticals NASDAQ:REGN

$493.24 -112.15 (-18.53%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$492.00 -1.24 (-0.25%)

As of 05/30/2025 07:59 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Takeda Pharmaceutical NYSE:TAK

$15.01 +0.21 (+1.42%)

Closing price 05/30/2025 03:59 PM Eastern

Extended Trading

$15.02 +0.02 (+0.10%)

As of 05/30/2025 07:05 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time